Abstract: Provided herein are novel bicyclic nucleosides, oligomeric compounds that include such bicyclic nucleosides and methods of using the oligomeric compounds. More particularly, the novel bicyclic nucleosides comprise a furanose ring system having a bridge comprising a 4?-methylene group attached to a 2?-sulfoxide or sulfone group and optionally including one or more substituent groups attached to the 4?-methylene and or the 5?-position. In certain embodiments, the oligomeric compounds provided herein are expected to hybridize to a portion of a target RNA resulting in loss of normal function of the target RNA.
Abstract: An active ingredient with cutaneous application obtained from Metschnikowia agaves, as well as its use for preventing and/or combating ageing of the skin and its visible manifestations, and cosmetic compositions including this active ingredient and to a cosmetic process for skin care.
Abstract: The present technology provides processes for cross-linking cellulose ethers under mild conditions. The processes include exposing a substantially dry cellulose ether film to a polyisocyanate to provide a cross-linked cellulose ether film, wherein the substantially dry cellulose ether film comprises alkoxide groups on the cellulose. The resulting cellulose ether films are highly cross-linked by polyurethane linkages and may be used as membranes in a variety of applications.
Abstract: Disclosed are compositions and formulations comprising glucosamine or a pharmaceutically acceptable salt thereof for use in the treatment of joint conditions and adapted for use in a bath or soak or bath beads, powders, salts, and oils, kits, and methods of treatment using the same. Also disclosed are lozenges, suppositories, patches, and topical creams comprising glucosamine or a pharmaceutically acceptable salt thereof for use in the treatment of joint conditions and methods of treatment using the same. In some embodiments the joint conditions include osteoarthritis.
Type:
Grant
Filed:
March 12, 2013
Date of Patent:
April 21, 2015
Assignee:
Vital Medicine, LLC
Inventors:
Anjan Chatterji, Grant Cooper, David Schwartz
Abstract: Disclosed herein are pharmaceutical compositions that can include a thionucleotide analog for use in combination therapy with other agents. Also disclosed herein are methods of treating diseases and/or conditions with a pharmaceutical composition that can include a thionucleotide analog in combination therapy with other agents.
Type:
Grant
Filed:
March 12, 2013
Date of Patent:
April 21, 2015
Assignee:
Alios BioPharma, Inc.
Inventors:
Lawrence M Blatt, Leonid Beigelman, Hua Tan, Julian Alexander Symons, David Bernard Smith, Min Jiang, Tara Lynn Kieffer, Cornelis Arie Rijnbrand
Abstract: This invention relates to a stereochemically pure uracyl spirooxetane nucleoside phosphoramidate useful in the treatment of patients infected with the hepatitis C virus (HCV).
Type:
Grant
Filed:
November 10, 2011
Date of Patent:
April 21, 2015
Assignees:
Janssen Products, LP, Medivir AB
Inventors:
Tim Hugo Maria Jonckers, Pierre Jean-Marie Bernard Raboisson, Koen Vandyck, Steven Maurice Paula Van Hoof, Lili Hu, Abdellah Tahri
Abstract: This invention provides a pharmaceutical solution formulation comprising tobramycin, water, sodium chloride and sodium citrate, wherein the formulation has a pH of 4.5-7.0 and an osmolality of 135-200 mOsmol/Kg.
Abstract: An agent for treatment of dry eye comprising a combination of a P2Y2 receptor agonist at a therapeutically effective concentration and hyaluronic acid or a salt thereof at a therapeutically effective concentration, which agent has a dosage form of an ophthalmic agent, can promote the secretion of tear remarkably and can improve corneal epithelial disorders remarkably, and is therefore expected to be a novel agent for treatment of dry eye.
Abstract: Flame retardant cellulose acetate is prepared comprising cellulose acetate flakes and an organophosphate compound bonded to the cellulose acetate flakes. Accordingly, the bonded phosphate-functional group provides the cellulose acetate flakes with pendant phosphate ester functionality. Numerous phosphate derivatives can be envisaged that will accomplish the intended task.
Type:
Grant
Filed:
January 4, 2013
Date of Patent:
April 7, 2015
Assignee:
International Business Machines Corporation
Abstract: There are provided compounds of the formula wherein X, Y, Z, R1, R2, R3 and R4 are as described herein and enantiomers and pharmaceutically acceptable salts and esters thereof. The compounds are useful as anticancer agents.
Type:
Grant
Filed:
March 5, 2013
Date of Patent:
March 31, 2015
Assignee:
F. Hoffmann-La Roche AG
Inventors:
David Joseph Bartkovitz, Xin-Jie Chu, Binh Thanh Vu, Chunlin Zhao, Daniel Fishlock
Abstract: The present disclosure provides tricyclic nucleosides, oligomeric compounds comprising at least one of the tricyclic nucleosides and methods of using the oligomeric compounds. The methods provided herein include contacting a cell or administering to an animal at least one of the oligomeric compounds. In certain embodiments, the oligomeric compounds hybridize to a portion of a target RNA resulting in loss of normal function of the target RNA.
Type:
Grant
Filed:
March 21, 2013
Date of Patent:
March 31, 2015
Assignee:
Isis Pharmaceuticals, Inc.
Inventors:
Eric E. Swayze, Andrew M. Siwkowski, Punit P. Seth, Thazha P. Prakash
Abstract: The present invention relates to a process for the production of alkali cellulose for the production of alkali cellulose and, optionally, cellulose ethers from cellulose in the presence of alkali and, if applicable, with alkylating and/or hydroxyalkylating agent(s) comprising the reaction of a cellulose with an alkali metal hydroxide, wherein the alkali metal hydroxide is mixed with cellulose in a mixing apparatus, the mixing apparatus (1) having an upper region (20, 102a, 202a) with a first cross-section and a lower region (21, 102b, 202b) with a second cross-section, the second cross-section being the same as or smaller than the first cross-section and comprising at least one non-horizontally oriented mixing device (23, 27, 121, 221, 224).
Abstract: Scaffold comprises a polymer defining macropores and comprising hydroxypropylcellulose partially substituted by a substituent comprising a self-crosslinkable group, which is crosslinked through the self-crosslinkable group. The macropores have an average pore size larger than 50 microns and are at least partially interconnected. In one method, bicontinuous emulsion comprising a continuous aqueous phase and a continuous polymer phase is formed. The polymer phase comprises hydroxypropylcellulose partially substituted by a substituent comprising a self-crosslinkable group, and is crosslinked through the self-crosslinkable group to form a polymer defining at least partially interconnected pores. In another method, phase separation is induced in a solution comprising a polymer precursor and water to form a bicontinuous emulsion comprising a continuous polymer phase and a continuous aqueous phase.
Type:
Grant
Filed:
September 12, 2012
Date of Patent:
March 31, 2015
Assignee:
Agency for Science, Technology and Research
Abstract: The present invention provides a composition of dietary fiber supplements for satiety enhancement and appetite suppression in treatment of overweight, obesity, or eating disorders. The composition of the dietary fiber supplements consist of at least one cationic polymer and at least one anionic polymer. The cationic polymers and the anionic polymers in the composition can be dissolved or dispersed in an aqueous solution. When the pH of the aqueous solution is lowered, such as the solution is ingested into the stomach with a gastric pH environment or the aqueous solution is added with some acidifying agents, the aqueous solution will turn into a gel. The formation of a gel from the aqueous solution after it being ingested into the stomach before a meal would provide a satiety enhancement and appetite suppression effect.
Abstract: The invention provides synthetic processes and synthetic intermediates that can be used to prepare compounds having useful anti-HIV properties.
Type:
Grant
Filed:
May 18, 2012
Date of Patent:
March 24, 2015
Assignee:
Gilead Sciences, Inc.
Inventors:
Richard Hung Chiu Yu, Brandon Heath Brown, Richard P. Polniaszek, Benjamin R. Graetz, Keiko Sujino, Duong Duc-Phi Tran, Alan Scott Triman, Kenneth M. Kent, Steven Pfeiffer
Abstract: The present invention describes sulodexide or at least one of its components for use in the reduction of circulating matrix metalloproteinase (MMPs), in particular MMP-9. Sulodexide and its composition are useful for the treatment of pathologies wherein the MMPs are involved, such as cardiovascular disease, cardiovascular disease caused by diabetes, varicose veins, chronic venous insufficiency (CVI), gastrointestinal ulcers, pulmonary disease, and neoplastic pathologies.
Type:
Grant
Filed:
April 20, 2011
Date of Patent:
March 24, 2015
Assignee:
Alfa Wassermann S.p.A.
Inventors:
Giuseppe Claudio Viscomi, Ferdinando Mannello, Cristiana Bruno
Abstract: The present disclosure relates to methods for the treatment of cancer in patients in recognized need of such treatment. The methods comprise administering to such a patient an NAE inhibitor or a pharmaceutically acceptable salt thereof, such as ((1S,2S,4R)-4-(4-((1S)-2,3-dihydro-1H-inden-1-ylamino)-7H-pyrrolo[2,3-d]pyrimidin-7-yl)-2-hydroxycyclopentyl)methyl sulfamate (MLN4924) or {(1S,2S,4R)-4-[(6-{[(1R,2S)-5-chloro-2-methoxy-2,3-dihydro-1H-inden-1-yl]amino}pyrimidin-4-yl)oxy]-2-hydroxycyclopentyl}methyl sulfamate (I-216), and a hypomethylating agent or a pharmaceutically acceptable salt thereof, such as azacitidine or decitabine. Also disclosed are medicaments for use in the treatment of cancer.
Abstract: This invention relates to synthesis of novel -N-FMOC protected nucleosides, succinates, phosphoramidites, corresponding solid supports that are suitable for oligo deoxy nucleosides and RNA oligonucleotide synthesis. Our discovery using N-FMOC as nucleoside base protecting group, which is highly base labile protecting group is a novel approach to obtain highest purity oligonucleotides. This approach is designed to lead to very high purity and very clean oligonucleotide, after efficient removal of the protecting groups and to produce high purity therapeutic grade DNA oligonucleotides, RNA oligonucleotides, diagnostic DNA, diagnostic RNA for microarray platform. The deprotection of FMOC protecting groups of the natural deoxy and ribonucleosides occurs under very mild deprotection conditions such as mild bases, secondary and tertiary amines for removal of such groups under such conditions would allows synthesis of various DNA and RNA of highest purity for diagnostics and therapeutic application.
Type:
Grant
Filed:
November 30, 2009
Date of Patent:
March 17, 2015
Assignee:
ChemGenes Corporation
Inventors:
Suresh C. Srivastava, Naveen P. Srivastava